EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events

Klinische Arzneimittelinteraktionen zwischen Voriconazol und 38 anderen Arzneimitteln: retrospektive Analyse von unerwünschten Ereignissen

Ben-Nian Huo, Ling Shu, Jian-Wen Xiao, Nan-Ge Yin, Mao-Lin Ai, Yun-Tao Jia, Lin Song

Frontiers in Pharmacology · 30.09.2024 · 15

DOI: 10.3389/fphar.2024.1292163 ↗

Auf einen Blick

Eine retrospektive Pharmakovigilanz-Analyse untersuchte unerwünschte Ereignisse bei Voriconazol-Interaktionen mit 38 Arzneimitteln. Bestimmte Ereignisse waren mit höheren Melderaten verbunden, und Geschlechts- sowie Altersunterschiede wurden beobachtet.

Fragestellung

Welche unerwünschten Ereignisse sind mit Arzneimittelinteraktionen von Voriconazol mit anderen Arzneimitteln verbunden, und spielen Geschlecht und Alter dabei eine Rolle?

Methode

Retrospektive Pharmakovigilanz-Studie mit OpenVigil FDA; Daten von Q1/2004 bis Q3/2022; Analyse mit vier statistischen Frequenzmodellen.

Ergebnisse

38 Arzneimittel, 262 AEs in mindestens einem Modell und 48 AEs in allen vier Modellen. 77 AEs waren signifikant positiv mit DDIs korreliert; für bestimmte Kombinationen wurden Geschlechts- und Altersunterschiede gefunden.

Schlussfolgerung der Autor:innen

Unerwünschte Ereignisse bei Voriconazol-Interaktionen sollten bei PPI, NSAID, Immunsuppressiva und anderen antibakteriellen Arzneimitteln stärker beachtet werden; Geschlecht und Alter sollten bei der Risikobewertung berücksichtigt werden.

Kernaussagen

  • 38 Arzneimittel mit Voriconazol untersucht
  • 77 AEs signifikant positiv mit DDIs korreliert
  • Geschlechts- und Altersunterschiede bei einigen Ziel-AEs

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.09.2024. Verfasst von Ben-Nian Huo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Minist…. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Voriconazole (VRZ) is involved in a variety of drug‒drug interactions (DDIs), but few studies have reported adverse events (AEs) associated with the DDIs of VRZ. The primary goal of this study was to analyse the potential risk factors for AEs caused by DDIs between VRZ and other drugs via the OpenVigil FDA platform and to provide a reference for preventing VRZ DDIs and monitoring clinically related adverse drug events.

Methods

A retrospective pharmacovigilance study was conducted to investigate the AEs related to DDIs between VRZ and four categories of drugs: proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and other antibacterial drugs. AE information for the target drugs from the first quarter of 2004 to the third quarter of 2022 was downloaded from the OpenVigil FDA data platform. Four frequency statistical models—the reporting ratio method, Ω shrinkage measure model, combination risk ratio model, and the chi-square statistics model—were used to analyse the AEs related to DDIs and evaluate the correlation and influence of sex and age between the drug(s) and the target AEs detected.

Results

A total of 38 drugs were included, with 262 AEs detected by at least one of the four models and 48 AEs detected by all four models. Some 77 detected AEs were significantly positively correlated with DDIs and were related to higher reporting rates of AEs than when used alone. Graft-versus-host disease was the AE that had the strongest correlation with the drug interaction between VRZ and immunosuppressants (tacrolimus, mycophenolate mofetil, cyclophosphamide, and cyclosporine), and multiple organ dysfunction syndrome was correlated with VRZ in combination with other antibacterial drugs (linezolid, meropenem, cefepime, and vancomycin). Significant sex and age differences in the target AEs were detected for five and nine target drugs, respectively. For VRZ in combination with linezolid, aggravated conditions and respiratory failure should be given more attention in male patients, and mycophenolate mofetil and respiratory failure in female patients. When conditions are aggravated, febrile neutropenia and septic shock should be of particular concern in patients over 18 years of age who use VRZ in combination with ceftazidime, ciprofloxacin, or cytarabine. In patients aged under 18, septic shock should be considered when VRZ is used in combination with meropenem and dexamethasone.

Conclusion

AEs related to DDIs should receive more attention when VRZ is used in combination with PPIs (renal impairment), NSAIDs (constipation and renal failure), immunosuppressants (graft versus host disease, septic shock) and other antibacterial drugs (multiple organ dysfunction syndrome, febrile neutropenia, and respiratory failure). Considering the influence of sex and age differences in VRZ DDIs, these factors need to be considered when assessing the risk of AEs in patients receiving VRZ and other drugs.

Schlagwörter

Stichwörter der Autor:innen

FAERSNSAIDsPPIsdrug–drug interactionimmunosuppressantssafetyvoriconazole

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Cho…
  • Department of Pharmacy, People's Hospital of Chongqing Liangjiang New Area, Chongqing, China.
  • Department of hematology, Children's Hospital of Chongqing Medical University, Chongqing, China.

Zitieren

APA

Huo, B. N., Shu, L., Xiao, J. W., Yin, N. G., Ai, M. L., Jia, Y. T., & Song, L. (2024). Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1292163

Vancouver

Huo BN, Shu L, Xiao JW, Yin NG, Ai ML, Jia YT, et al. Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1292163

BibTeX
@article{Huo2024,
  author = {Huo, Ben-Nian and Shu, Ling and Xiao, Jian-Wen and Yin, Nan-Ge and Ai, Mao-Lin and Jia, Yun-Tao and Song, Lin},
  title = {Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1292163}
}
Kostenlos starten →